Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.45 |
| ▸ | MTOR | P42345 | 3/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20740505 | 0.98 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1HRH3PIK3CAMTOR | |
| SCHEMBL20740625 | 0.98 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1HRH3PIK3CAMTOR | |
| SCHEMBL20740477 | 0.97 | HRH3 (0.48) | L3MBTL3L3MBTL1HRH3PIK3CAMTOR | |
| SCHEMBL13769052 | 0.94 | PIK3CA (0.50) | L3MBTL3L3MBTL1HRH3PIK3CAMTOR | |
| SCHEMBL2300495 | 0.88 | MAP4K4 (0.49) | L3MBTL3L3MBTL1HRH3PIK3CAMTOR | |
| SCHEMBL13769029 | 0.88 | L3MBTL3 (0.64) | L3MBTL3L3MBTL1HRH3KCNH2 | |
| SCHEMBL2724459 | 0.86 | L3MBTL3 (0.62) | L3MBTL3L3MBTL1HRH3KCNH2 | |
| SCHEMBL10126764 | 0.84 | ACVR1 (0.53) | L3MBTL3L3MBTL1PIK3CAMTOR | |
| SCHEMBL14916901 | 0.83 | PIK3CA (0.50) | PIK3CAMTORHSD11B1CHRNB2CHRNA4 | |
| SCHEMBL2724584 | 0.81 | L3MBTL1 (0.46) | L3MBTL3L3MBTL1HRH3PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444254-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) | 2019-03-07 | — | — | US | disclosed |
| EP-3444254-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CDK4, CDK6, CCNI | L3MBTL3 3930/4885L3MBTL1 3334/4885HRH3 2208/4885 |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | CDK4, CDK6, CCNI | L3MBTL3 3930/4885L3MBTL1 3334/4885HRH3 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.